ABSTRACT:
The two main problems with most biologically active compounds are their slow rate of breakdown and their difficulty in dissolving in water. As a member of BCS class IV, cefpodoxime proxetil has limited permeability and solubility. To increase the drug's solubility and rate of dissolution, the current study set out to create Cefpodoxime proxetil nanosuspension utilizing a solvent evaporation technique. Zeta potential, particle size, total drug content, and entrapment efficiency were assessed for the created nanosuspension formulation. Various polymers were used to create stable nanosuspension over various trial batches. Following the findings of trial batches, the polyvinylpyrrolidone k30 was selected using a 23 factorial design for the production of cefpodoxime proxetil nanosuspension. With a %Entrapment efficiency of 96.16±0.55%, batch F4 exhibited the highest percentage among the analyzed formulation batches. Among the batches, the F4 batch has the highest total drug concentration, measuring 95.61±0.32%. Every batch of nanosuspension was assessed for several characteristics; batch F4 exhibited the lowest values for the maximum zeta potential (35.4 mV), polydispersity index (0.042 ± 0.01), and particle size (160.6 ± 1.2nm), in that order. For optimization, a linear model was mostly employed. The results of the ANOVA showed that the F4 batch was the most productive. Polyvinylpyrrolidone K30 and tween 80 were used to create a stable nanosuspension that improved the solubility and subsequent release of pure Cefpodoxime proxetil medication.